REG - Poolbeg Pharma PLC - Annual Report, AGM Notice & Circular

Poolbeg PharmaAnnouncement

Yesterday 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250527:nRSa0619Ka&default-theme=true

RNS Number : 0619K  Poolbeg Pharma PLC  27 May 2025

Poolbeg Pharma plc

 

Annual Report, AGM Notice & Circular

27 May 2025 - Poolbeg Pharma
(https://url.avanan.click/v2/___http:/www.poolbegpharma.com/___.YXAxZTpzaG9yZWNhcDphOm86NmUxMjE5MmVmMDQxMWM1NDQ0MzEyNjAxM2Q4ZGMxNGQ6NjphMjdiOmNlODgwYTlkZDQzYzYxZDU0ODk4NmRhZDY2ZDU4MWIyYjFlNWE2ZTRmYWU0M2I5MzFhOWE2ZmE2ZTM1NDViZjE6cDpUOk4)
 (AIM: POLB, 'Poolbeg' or the 'Company'), a clinical-stage
biopharmaceutical company focussed on the development of innovative medicines
to address unmet medical needs, confirms that the Company's Annual Report and
Accounts for the period ended 31 December 2024 and the notice of Annual
General Meeting ("AGM") will be posted to shareholders today.

 

The 2024 Annual Report and Accounts, the Notice of AGM and accompanying form
of proxy are available to download from the Company's website:
www.poolbegpharma.com
(https://url.avanan.click/v2/___http:/www.poolbegpharma.com___.YXAxZTpzaG9yZWNhcDphOm86NmUxMjE5MmVmMDQxMWM1NDQ0MzEyNjAxM2Q4ZGMxNGQ6Njo2MDk2OmQ1Y2MwYTQyYzljOGVhYWFlNTBiOWQwN2M1YWM1MTYwNjNmYjZlMjg2NjdiNjU3Yzc3ZDMwZWRmZjM3MzIxZjQ6cDpUOk4)
 

 

The Annual General Meeting will be held at the offices of DAC Beachcroft LLP,
25 Walbrook, London EC4N 8AF, United Kingdom at 12pm on 23 June 2025.

 

Further to the Company's announcement on 20 May 2025
(https://url.avanan.click/v2/___https:/www.londonstockexchange.com/news-article/POLB/result-of-placing-and-notice-of-general-meeting/17045961___.YXAxZTpzaG9yZWNhcDphOm86NmUxMjE5MmVmMDQxMWM1NDQ0MzEyNjAxM2Q4ZGMxNGQ6NjowYjg1OjY0YTk2MDBlZmM5ZWIxMjBjNDE0NDYzODgxZjVkOGVkMzEyYTc2MDA2NWFkOThiNzJkNWNiMzAzNGM2ZDdlY2Y6cDpUOk4)
, a Circular containing details of the Fundraising and convening a general
meeting, along with an accompanying form of proxy, will also be posted to
Shareholders today. The Circular is available on the Company's website
at www.poolbegpharma.com
(https://url.avanan.click/v2/___http:/www.poolbegpharma.com___.YXAxZTpzaG9yZWNhcDphOm86NmUxMjE5MmVmMDQxMWM1NDQ0MzEyNjAxM2Q4ZGMxNGQ6Njo2MDk2OmQ1Y2MwYTQyYzljOGVhYWFlNTBiOWQwN2M1YWM1MTYwNjNmYjZlMjg2NjdiNjU3Yzc3ZDMwZWRmZjM3MzIxZjQ6cDpUOk4)
.

 

Enquiries

 

 Poolbeg Pharma Plc                                              +44 (0) 207 183 1499

 Jeremy Skillington, CEO                                         ir@poolbegpharma.com

 Ian O'Connell, CFO

 Cavendish Capital Markets Ltd (NOMAD & Joint Broker)            +44 (0) 207 220 0500

 Geoff Nash, Trisyia Jamaludin (Corporate Finance)

 Nigel Birks (Life Science Specialist Sales)

 Harriet Ward (ECM)

  
 Shore Capital Stockbrokers Ltd (Joint Broker)                   +44 (0) 207 408 4090

 David Coaten, Harry Davies-Ball (Corporate Advisory)

Malachy McEntyre, Isobel Jones (Corporate Broking)

 J&E Davy (Joint Broker)                                         +353 (0) 1 679 6363

 Anthony Farrell, Niall Gilchrist

  
 Optimum Strategic Communications                                +44 (0) 208 078 4357

 Nick Bastin, Vici Rabbetts, Elena Bates                         poolbeg@optimumcomms.com (mailto:poolbeg@optimumcomms.com)

  

 

About Poolbeg Pharma plc

Poolbeg Pharma plc is a clinical-stage biopharmaceutical company focussed on
the development of innovative medicines to address unmet medical needs. The
Company's clinical programmes target large addressable markets including,
cancer immunotherapy-induced Cytokine Release Syndrome ("CRS") and metabolic
conditions such as obesity with the development of an oral encapsulated
glucagon-like peptide GLP-1R agonist.

 

For more information, please go to www.poolbegpharma.com
(https://url.avanan.click/v2/___https:/www.poolbegpharma.com/___.YXAxZTpzaG9yZWNhcDphOm86MDEyNWViMjlmNzZkZWZiMmRjNTc2MjQ5ZTRkN2Q1YjM6NjozYmY0OmJiMDhkZWIyZjlkYjAxNDhhMmNkMmZhZTgyOGI2ZTI3MjgwYTVmYjdmOTk5YjRjYjVjNDBjMDAyMzVmOGRjM2U6cDpGOk4)
 or follow us on Twitter
(https://url.avanan.click/v2/___https:/twitter.com/PoolbegPharma___.YXAxZTpzaG9yZWNhcDphOm86MDEyNWViMjlmNzZkZWZiMmRjNTc2MjQ5ZTRkN2Q1YjM6NjphMmQ2OmZhNGMwMmExOWVkOGRjZDBkY2MyMGRiYTk3MTY2YjliYzU1ZjM4MTg1NjAxZTZjNmQwN2UyNjI2NmQ0M2RkNzk6cDpGOk4)
and LinkedIn
(https://url.avanan.click/v2/___https:/www.linkedin.com/company/poolbeg-pharma/___.YXAxZTpzaG9yZWNhcDphOm86MDEyNWViMjlmNzZkZWZiMmRjNTc2MjQ5ZTRkN2Q1YjM6NjozNGNlOjVjNTk4MTc1NmY1YjA3YWNlMGI3NjkzZDFhNWExZjVkYjhjNzcyZDlhZmE1OTY4ZWQ0M2Q0Y2JjM2JiZGQ1OTM6cDpGOk4)
@PoolbegPharma.

 

Forward-Looking Statements

This announcement may contain forward-looking statements and the words
"expect", "anticipate", "intends", "plan", "estimate", "aim", "forecast",
"project" and similar expressions (or their negative) identify certain of
these forward-looking statements. The forward-looking statements in this
announcement are based on numerous assumptions and Poolbeg's present and
future business strategies and the environment in which Poolbeg expects to
operate in the future. Forward-looking statements involve inherent known and
unknown risks, uncertainties and contingencies because they relate to events
and depend on circumstances that may or may not occur in the future and may
cause the actual results, performance or achievements to be materially
different from those expressed or implied by such forward-looking statements.
These statements are not guarantees of future performance or the ability to
identify and consummate investments. Many of these risks and uncertainties
relate to factors that are beyond Poolbeg's ability to control or estimate
precisely, such as future market conditions, currency fluctuations, the
behaviour of other market participants, the outcome of clinical trials, the
actions of regulators and other factors such as Poolbeg's ability to obtain
financing, changes in the political, social and regulatory framework in which
Poolbeg operates or in economic, technological or consumer trends or
conditions. Past performance should not be taken as an indication or guarantee
of future results, and no representation or warranty, express or implied, is
made regarding future performance. No person is under any obligation to update
or keep current the information contained in this announcement or to provide
the recipient of it with access to any additional relevant information.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NOAQXLFLEELXBBB